StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Welireg (belzutifan by Quarter

Welireg (belzutifan — HIF-2α inhibitor) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Welireg (belzutifan: 67.0% in Q2 2026, up 38.0 pts from a year earlier.

Latest, Q2 2026
67.0%
Period ended Jun 30, 2026
Change on a year earlier
+38.0 pts
29.0% in Q2 2025
History
13 quarters
Since Q1 2023
Sources
13
Documents cited below

Where the Q2 2026 figure comes from

“|| Welireg | 271 | 162 | 67 | 214 | 138 | 55 | 57 | 24 | 133”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWelireg (belzutifan — HIF-2α inhibitor) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202667.0%+38.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202537.0%-85.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202542.0%-114.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202529.0%-121.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 202562.0%-40.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024122.0%+43.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024156.0%+113.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 2024150.0%+61.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024102.0%-26.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202379.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202343.0%–Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202389.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023128.0%–Form 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗

Cite this data

StockData. (2026). Merck Welireg (belzutifan (%), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-welireg-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.